The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease
Open accessAbstract
BACKGROUND: The results from controlled clinical trials investigating the efficacy of azathioprine and 6-mercaptopurine for the treatment of active Crohn's disease have been conflicting and controversial. An updated meta-analysis was performed to assess the effectiveness of these drugs for the induction of remission in active Crohn's disease. OBJECTIVES: The primary objective was to determine the efficacy and safety of azathioprine and 6-mercaptopurine for induction of remission in active Crohn's disease. SEARCH METHODS: We searched MEDLINE, EMBASE and the Cochrane Library from inception to 30 October 2015. Review articles and conference proceedings were also searched to identify additional studies. SELECTION CRITERIA: Randomized controlled trials (RCTs) of oral azathioprine or 6-mercaptopurine compared to placebo or active therapy involving adult patients with active Crohn's disease were selected for inclusion. DATA COLLECTION AND ANALYSIS: Data were extracted by two independent observers based on the intention-to-treat principle. Outcomes of interest included: clinical remission, clinical improvement, fistula improvement or healing, steroid sparing, adverse events, withdrawals due to adverse events and serious adverse events. We calculated the pooled relative risk (RR) and 95% confidence intervals (95% CI) for each outcome. The methodological quality of included studies was evaluated using the Cochrane risk of bias tool. The overall quality of the evidence supporting each outcome was assessed using the GRADE criteria. MAIN RESULTS: Thirteen RCTs (n = 1211 patients) of azathioprine and 6-mercaptopurine therapy in adult patients were identified: nine included placebo comparators and six included active comparators. The majority of included studies were rated as low risk of bias. There was no statistically significant difference in clinical remission rates between azathioprine or 6-mercaptopurine and placebo. Forty-eight per cent (95/197) of patients receiving antimetabolites achieved remission compared to 37% (68/183) of placebo patients (5 studies, 380 patients; RR 1.23, 95% CI 0.97 to 1.55). There was no statistically significant difference in clinical improvement rates between azathioprine or 6-mercaptopurine and placebo. Forty-eight per cent (107/225) of patients receiving antimetabolites achieved clinical improvement or remission compared to 36% (75/209) of placebo patients (8 studies, 434 patients; RR 1.26, 95% CI 0.98 to 1.62). There was a statistically significant difference in steroid sparing (defined as prednisone dose < 10 mg/day while maintaining remission) between azathioprine and placebo. Sixty-four per cent (47/163) of azathioprine patients were able to reduce their prednisone dose to < 10 mg/day compared to 46% (32/70) of placebo patients (RR 1.34, 95% CI 1.02 to 1.77). GRADE analyses rated the overall quality of the evidence for the outcomes clinical remission, clinical improvement and steroid sparing as moderate due to sparse data. There was no statistically significant difference in withdrawals due to adverse events or serious adverse events between antimetabolites and placebo. Ten percent of patients in the antimetabolite group withdrew due to adverse events compared to 5% of placebo patients (8 studies, 510 patients; RR 1.70, 95% CI 0.94 to 3.08). Serious adverse events were reported in 14% of patients receiving azathioprine compared to 4% of placebo patients (2 studies, 216 patients; RR 2.57, 95% CI 0.92 to 7.13). Common adverse events reported in the placebo controlled studies included: allergic reactions. leukopenia, pancreatitis and nausea. Azathioprine was significantly inferior to infliximab for induction of steroid-free clinical remission. Thirty per cent (51/170) of azathioprine patients achieved steroid-free remission compared to 44% (75/169) of infliximab patients (1 study, 339 patients; RR 0.68, 95% CI 0.51 to 0.90). The combination of azathioprine and infliximab was significantly superior to infliximab alone for induction of steroid-free clinical remission. Sixty per cent (116/194) of patients in the combined azathioprine and infliximab group achieved steroid-free remission compared to 48% (91/189) of infliximab patients (2 studies, 383 patients; RR 1.23, 95% CI 1.02 to 1.47). Azathioprine or 6-mercaptopurine therapy was found to be no better at inducing steroid free clinical remission compared to methotrexate (RR 1.13, 95% CI 0.85 to 1.49) and 5-aminosalicylate or sulfasalazine (RR 1.24, 95% CI 0.80 to 1.91). There were no statistically significant differences in withdrawals due to adverse events between azathioprine or 6-mercaptopurine and methotrexate (RR 0.78, 95% CI 0.23 to 2.71); between azathioprine or 6-mercaptopurine and 5-aminosalicylate or sulfasalazine (RR 0.98, 95% CI 0.38 to 2.54); between azathioprine and infliximab (RR 1.47, 95% CI 0.96 to 2.23); or between the combination of azathioprine and infliximab and infliximab (RR 1.16, 95% CI 0.75 to 1.80). Common ad
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
(2008) · Cited by 3,790
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
Colombel, J. F., Sandborn, W. J., Reinisch, W., Mantzaris, G. J., Kornbluth, A., Rachmilewitz, D., Lichtiger, S., D'Haens, G., Diamond, R. H., Broussard, D. L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0904492 · Cited by 3,143
A method for assessing the quality of a randomized control trial
Chalmers, T. C., Smith, H., Blackburn, B., Silverman, B., Schroeder, B., Reitman, D., & Ambroz, A. (1981) · Controlled Clinical Trials · doi:10.1016/0197-2456(81)90056-8 · Cited by 1,349
National Cooperative Crohn's Disease Study: Results of drug treatment
Summers, R. W., Switz, D. M., Sessions, J. T., Becktel, J. M., Best, W. R., Kern, F., & Singleton, J. W. (1979) · Gastroenterology · doi:10.1016/0016-5085(79)90385-8 · Cited by 1,239
D'Haens, G., Baert, F., van Assche, G., Caenepeel, P., Vergauwe, P., Tuynman, H., De Vos, M., van Deventer, S., Stitt, L., Donner, A., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60304-9 · Cited by 1,231
Weinshilboum, R. M., & Sladek, S. L. (1980) · PubMed · Cited by 1,195
Published by John Wiley & Sons Ltd
Modarresi, O. A. F., & Shakibaie, M. M. M. R. (2015) · Cited by 1,111
Treatment of Crohn's Disease with 6-Mercaptopurine: A Long-Term, Randomized, Double-Blind Study
Present, D. H., Korelitz, B. I., Wisch, N., Glass, J. L., Sachar, D. B., & Pasternack, B. S. (1980) · New England Journal of Medicine · doi:10.1056/nejm198005013021801 · Cited by 1,042
Cited by
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
Dignass, A., Van Assche, G., Lindsay, J. O., Lémann, M., Söderholm, J., Colombel, J. F., Danese, S., D'Hoore, A., Gassull, M., Gomollón, F., et al. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.12.002 · Cited by 1,498
ACG Clinical Guideline: Management of Crohn's Disease in Adults
Lichtenstein, G. R., Loftus, E. V., Isaacs, K. L., Regueiro, M. D., Gerson, L. B., & Sands, B. E. (2018) · American Journal of Gastroenterology · doi:10.1038/ajg.2018.27 · Cited by 1,421
Guidelines for the management of inflammatory bowel disease in adults
Mowat, C., Cole, A., Windsor, A., Ahmad, T., Arnott, I., Driscoll, R., Mitton, S., Orchard, T., Rutter, M., Younge, L., et al. (2011) · Gut · doi:10.1136/gut.2010.224154 · Cited by 1,419
Management of Crohn's Disease in Adults
Lichtenstein, G. R., Hanauer, S. B., & Sandborn, W. J. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.168 · Cited by 1,173
Guidelines for the management of inflammatory bowel disease in adults
Carter, M. J., Lobo, A. J., & Travis, S. P. L. (2004) · Gut · doi:10.1136/gut.2004.043372 · Cited by 1,083
Roda, G., Chien Ng, S., Kotze, P. G., Argollo, M., Panaccione, R., Spinelli, A., Kaser, A., Peyrin-Biroulet, L., & Danese, S. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0156-2 · Cited by 1,023
The Medical Management of Paediatric Crohn’s Disease: an ECCO-ESPGHAN Guideline Update
van Rheenen, P. F., Aloi, M., Assa, A., Bronsky, J., Escher, J. C., Fagerberg, U. L., Gasparetto, M., Gerasimidis, K., Griffiths, A., Henderson, P., et al. (2021) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjaa161 · Cited by 729
Evidence-based clinical practice guidelines for inflammatory bowel disease
Matsuoka, K., Kobayashi, T., Ueno, F., Matsui, T., Hirai, F., Inoue, N., Kato, J., Kobayashi, K., Kobayashi, K., Koganei, K., et al. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-018-1439-1 · Cited by 698
Travis, S. P. L., Stange, E. F., Lémann, M., Öresland, T., Chowers, Y., Forbes, A., D’Haens, G., Kitis, G., Cortot, A., Prantera, C., et al. (2006) · Gut · doi:10.1136/gut.2005.081950b · Cited by 597
A comprehensive review and update on Crohn's disease
Gajendran, M., Loganathan, P., Catinella, A. P., & Hashash, J. G. (2018) · Disease-a-Month · doi:10.1016/j.disamonth.2017.07.001 · Cited by 550
Crohn Disease: Epidemiology, Diagnosis, and Management
Feuerstein, J. D., & Cheifetz, A. S. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.04.010 · Cited by 548
Evidence-based clinical practice guidelines for inflammatory bowel disease 2020
Nakase, H., Uchino, M., Shinzaki, S., Matsuura, M., Matsuoka, K., Kobayashi, T., Saruta, M., Hirai, F., Hata, K., Hiraoka, S., et al. (2021) · Journal of Gastroenterology · doi:10.1007/s00535-021-01784-1 · Cited by 505
An Update on Inflammatory Bowel Disease
Sairenji, T., Collins, K. L., & Evans, D. V. (2017) · Primary Care: Clinics in Office Practice · doi:10.1016/j.pop.2017.07.010 · Cited by 499
Dubinsky, M. C., Yang, H., Hassard, P. V., Seidman, E. G., Kam, L. Y., Abreu, M. T., Targan, S. R., & Vasiliauskas, E. A. (2002) · Gastroenterology · doi:10.1053/gast.2002.32420 · Cited by 483
Hanauer, S. B., Korelitz, B. I., Rutgeerts, P., Peppercorn, M. A., Thisted, R. A., Cohen, R. D., & Present, D. H. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.06.002 · Cited by 460
Clinical pharmacology and pharmacogenetics of thiopurines
Sahasranaman, S., Howard, D., & Roy, S. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0478-6 · Cited by 405
Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease
Chande, N., Patton, P. H., Tsoulis, D. J., Thomas, B. S., & MacDonald, J. K. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000067.pub3 · Cited by 402
Self-citationAn Evidence-Based Systematic Review on Medical Therapies for Inflammatory Bowel Disease
Talley, N. J., Abreu, M. T., Achkar, J.-P., Bernstein, C. N., Dubinsky, M. C., Hanauer, S. B., Kane, S. V., Sandborn, W. J., Ullman, T. A., & Moayyedi, P. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.58 · Cited by 310
Dassopoulos, T., Sultan, S., Falck–Ytter, Y. T., Inadomi, J. M., & Hanauer, S. B. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.10.046 · Cited by 297
Current and emerging drugs for the treatment of inflammatory bowel disease
Triantafillidis, J. (2011) · Drug Design, Development and Therapy · doi:10.2147/dddt.s11290 · Cited by 289
Hazlewood, G. S., Rezaie, A., Borman, M., Panaccione, R., Ghosh, S., Seow, C. H., Kuenzig, E., Tomlinson, G., Siegel, C. A., Melmed, G. Y., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.10.011 · Cited by 276
Methotrexate for induction of remission in refractory Crohn's disease
McDonald, J. W., Wang, Y., Tsoulis, D. J., MacDonald, J. K., & Feagan, B. G. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003459.pub4 · Cited by 270
Self-citationTreatment of inflammatory bowel disease: A review of medical therapy
Kozuch, P. L., & Hanauer, S. B. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.354 · Cited by 261
Thiopurine-Induced Myelotoxicity in Patients With Inflammatory Bowel Disease: A Review
Gisbert, J. P., & Gomolln, F. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.01848.x · Cited by 253
Inflammatory bowel disease – non-biological treatment
Magro, F., Cordeiro, G., Dias, A. M., & Estevinho, M. M. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105075 · Cited by 77
Calvet, X., Gallardo, O., Coronas, R., Casellas, F., Montserrat, A., Torrejón, A., Vergara, M., Campo, R., & Brullet, E. (2006) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200608000-00004 · Cited by 45
Helminth therapy (worms) for induction of remission in inflammatory bowel disease
Garg, S. K., Croft, A. M., & Bager, P. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009400.pub2 · Cited by 39
Probiotics in inflammatory bowel disease: Does it work?
Silva, N. O. E., Brito, B. B. D., Silva, F. A. F. D., Santos, M. L. C., & Melo, F. F. D. (2020) · World Journal of Meta-Analysis · doi:10.13105/wjma.v8.i2.54 · Cited by 17
Metadata
- Authors
- Prefontaine, E., MacDonald, J. K., & Sutherland, L. R.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2010-06-16
- Volume
- 10
- Issue
- 6
- Pages
- CD000545-CD000545
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W2072179061
- Cited by
- 604
- References
- 64
- Type
- reference entry
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.